Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations; presence of N-nitroso-duloxetine impurity above the FDA recommended limit
| Brand name | DULOXETINE |
| Generic name | DULOXETINE HYDROCHLORIDE |
| Active ingredient(s) | DULOXETINE HYDROCHLORIDE |
| Distributed by / for | Quallient Pharmaceuticals Health, LLC, Grand Cayman, Cayman Islands |
| NDC | 82009-032-10 |
| Full product label | Duloxetine Delayed-Release Capsules, USP, 60 mg, 1000-Capsule bottles, Rx Only, Manufactured by: Towa Pharmaceuticals Europe, S.L. Marotrelles, (Barcelona), Spain, Manufactured for : Quallient Pharmaceuticals Health, LLC, Grand Cayman, Cayman Islands, NDC 82009-032-10. |
| Recalling firm | Breckenridge Pharmaceutical, Inc. |
| Distribution | Nationwide within the United States |
| Quantity | 3397 bottles |
| Recall initiated | 2025-11-24 |
| Report date | 2025-12-10 |
| Recall completed | — |
| Recall number | D-0215-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Berkeley Heights NJ United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗